DYNAMICS OF THE ACUTE VIRAL HEPATITISES MORBIDITY AND RANGE OF MEDICINAL PREPARATIONS FOR TREATMENT IN HOSPITAL ENVIRONMENT IN THE VOLGOGRAD REGION (THE RUSSIAN FEDERATION), 2016–2018

L.M. Ganicheva1, E.A. Ioannidi1, O.A. Panfilova1, I.N. Tyurenkov2, Yu.S. Knyazeva1, N.Sh. Kaysheva2

1 Volgograd State Medical University, 1, Pavshikh Boytsov Sq., Volgograd, Russia, 400131
2 Pyatigorsk Medical and Pharmaceutical Institute, branch of Volgograd State Medical University 11, Kalinin ave, Pyatigorsk, Russia 357532

E-mail: olesya.panfilova.95@mail.ru

Received 18 July 2019 Review (1) 15 October 2019 Review (2) 20 October 2019 Accepted: 28 December 2019

The aim of the study was to investigate the prevalence of acute viral hepatitises A, B and C in the Volgograd region; the range and identification of the most frequently prescribed pharmacological groups to be used in hospital environment; and analyzing the price dynamics of medicines. These factors will make it possible to assess the state of the medicine provision for the patients with this disease in hospital environment.

Materials and methods. In the study, the following methods have been used: comparison, a method of grouping indicators and a structural-logical method. The materials were the hepatological department patients’ treatment sheets (Volgograd Regional Clinical Infectious Diseases Hospital N1).

Results. Acute hepatitis A is the most common (46.9%), acute hepatitis B occupies the second position (27.4%), and acute hepatitis C – the third one (25.7%), where in 46.2%, 23.5% and 14.7%, respectively, are accounted for by icteric viral hepatitis. Hepatoprotectors, symptomatic medications and rehydration and detoxification medicinal preparations are prescribed for all forms and degrees of the disease severity.

Conclusion. The study has revealed a decreased morbidity of acute viral hepatitises A, B and an increased morbidity of acute viral hepatitis C in the Volgograd region. Among all the types of hepatitises, the prevailing one is the icteric form of moderate severity. The range of medicinal preparations prescribed for the treatment of acute viral hepatitises has been studied. Most often, doctors prescribe hepatoprotectors, rehydration and detoxification medicinal preparations. The study of price dynamics, showed a predominant increase in hepatoprotectors and a decrease in medicines for rehydration and detoxification. The results obtained indicate a tendency towards the improvement of drug provision in the Volgograd Region, for the patients with acute viral hepatitises. Besides, the results of the study give an opportunity to consider the ways of its further optimization.

Keywords: acute viral hepatitis, the form and severity of the disease, range of medicinal preparations

Abbreviations: ATC – Anatomical Therapeutic Chemical Classification System; HAV – viral hepatitis A; HBV – hepatitis B virus; HCV – viral hepatitis C; SRMP – state register of medicinal preparations; VEDL – Vital and Essential Drugs List; AVH – acute viral hepatitis.
Цель. Исследование распространенности острых вирусных гепатитов А, В и С в Волгоградском регионе, изучение ассоциатума, выявление наиболее часто назначаемых фармакологических групп для стационарного лечения и анализ динамики цен на лекарственные препараты, что позволит оценить состояние лекарственного обеспечения пациентов с данным заболеванием в условиях стационара.

Материалы и методы. Использовались методы сравнения, группировки показателей и структурно-логический. Материалами послужили листы назначений пациентов гепатологического отделения Волгоградской областной клинической инфекционной больницы №1.

Результаты. Наиболее распространенными являются острые гепатиты А и В. Острый гепатит А – 46,9%, острый гепатит В – 27,4%, острый гепатит С – 25,7%, из которых соответственно 46,2%, 23,5% и 14,7% приходится на желтушную форму средней тяжести. При всех формах и степенях тяжести заболевания назначают гепатопротекторы, симптоматические препараты и препараты для регидратации, дезинтоксикации. Заключение. За исследуемый период в Волгоградском регионе выявлено снижение заболеваемости острыми вирусными гепатитами А и В, но, в свою очередь, и рост заболеваемости острым вирусным гепатитом С. Преобладающей среди всех видов гепатита является желтушная форма средней степени тяжести. Изучаем ассортимент лекарственных препаратов, применяемых при лечении острых вирусных гепатитов в Волгоградской областной клинической инфекционной больнице №1. Наиболее часто врачи назначают гепатопротекторы, препараты для регидратации, дезинтоксикации. Изучение динамики цен показало преимущество повышение на гепатопротекторы и понижение на препараты для регидратации и дезинтоксикации. Полученные результаты свидетельствуют о тенденции к улучшению лекарственного обеспечения в Волгоградском регионе пациентов с острыми вирусными гепатитами и позволяют рассмотреть пути его дальнейшей оптимизации.

Ключевые слова: острый вирусный гепатит, форма и степень тяжести заболевания, ассоциатум лекарственных препаратов

Список сокращений: АТХ – анетаматерапевтическо-химическая классификация; ВГА – вирусный гепатит А; ВГВ – вирусный гепатит B; ВГС – вирусный гепатит C; ГРС – государственный реестр лекарственных препаратов; ЖНВЛП – перечень жизненно необходимых и важнейших лекарственных препаратов; ОВГ – острый вирусный гепатит.

INTRODUCTION

Viral hepatitis is a widespread infectious disease that destroys a human liver. According to the World Health Organization, hundreds of millions of people in different countries are infected with viral hepatitis, which exceed the spread of HIV infections. Hepatitis is a medical and social problem both for the Russian Federation and for the whole world. A decrease in the incidence of acute hepatitis, is associated with increased preventive measures and the introduction of vaccination in accordance with the national vaccination calendar. Vaccination against viral hepatitis A (HAV) and B (HBV) has been carried out in Russia for the past 20 years, but a vaccine against viral hepatitis C (HCV) has not been developed due to the severe variability of the virus genome. The main reason for the carrier state of this hepatitis virus is the epidemiological problems of countries over the previous 20–25 years. About 650 thousand deaths per year in the world are associated with hepatitis B virus. 2–3% of the Russia population, are infected with hepatitis C. The main routes of HBV and HCV transmission are parenteral, contact (through a skin microtrauma, sexual promiscuity), and the vertical routes (from a mother to a child).

The mechanism of HCV transmission is the fecal-oral route. As the practical data have shown, in the Volgograd Region, the main route of hepatitis B infection is the parenteral route (administration of narcotic substances with non-sterile needles in drug addiction).

Viral hepatitis A is the most common and, although this disease is typical of the third world countries, rare cases or outbreaks of hepatitis A are also observed in developed countries. In the Russian Federation, HAV is the most common (more than 50% of cases). In its turn, mortality rate due to HAV is low and accounts for a fraction of a percent worldwide. About 1.5 million cases of HAV have been registered in the world annually, and in the Russian Federation in 2010, the mortality rate was 6.3 cases per 100 thousand people. High incidence of the disease is associated with the active release of HAV (hepatitis A virus) from the patient’s body and its high resistance to the environment. As a rule, chronic hepatitis A does not develop when it comes to a single-agent infection. [10, 11].

In the Russian Federation in 2012, acute hepatitis B amounted to 1.43 cases per 100 thousand people. Thanks to the vaccination, the morbidity decreased by 30 times in 2000–2012. 90–95% of adults with HBV recover and only 10% have the chronic form. The mortality rate due to acute hepatitis B is less than 1%. In the Volgograd region in 2015, the morbidity of acute hepatitis B was 1.7 times lower than its morbidity rate in the Russian Federation, in 2015 it amounted to 0.78 cases per 100 thousand people, in 2016 it was 0.54 [12, 13].

In the Russian Federation in 2012, acute hepatitis C amounted to 1.8 cases per 100 thousand people. 50–80% of the infected people have a chronic form. In the Volgograd region in 2015, the morbidity of acute hepatitis B amounted to 0.66 per 100 thousand people, which is 2.1 times lower than the average rate of this disease in the Russian Federation, and in 2016 it amounted to 0.16 [14].

THE AIM of the study was to investigate the state of affairs in acute viral hepatitis A, B and C in the Volgograd region during the period of 2016–2018: its prevalence, the forms and severity of the disease, the range of medicinal preparations used in hospitals for the acute hepatitis treatments, the dynamics of prices for medicines of the most widely used pharmacological groups based on the state register of medicinal preparations.

Early disease and treatment intelligence plays an important role in preventing health complications and saving budget funds, of both the state and the population.

MATERIALS AND METHODS

In the study, the following methods have been used: comparison, a method of grouping indicators and a structural-logical method. The materials were 175 hepatological department patients’ treatment sheets (Volgograd Regional Clinical Infectious Diseases Hospital No.1) and the data of the state register of medicinal preparations of the Russian Federation.

The research design is represented by 4 interconnected stages:
1 – the analysis of the morbidity dynamics of acute viral hepatitis A, B, C;
2 – the analysis of the data on the duration of treatment in hospital environment;
3 – the detection of the most significant range groups of medicinal preparations for the treatment of acute viral hepatitises A, B, C.

4 – the analysis of the dynamics of prices for the medicinal preparations prescribed for the treatment of acute viral hepatitises.

RESULTS AND DISCUSSION

Viral hepatitises are classified according to the form and severity of the disease [15,16]. In the infectious hospital during 2016–2018, the following forms were registered:

– the icteric form (moderate and heavy severity level); and
– the anicteric form (mild and moderate severity level).

At the first stage of the study, the analysis of the morbidity dynamics of the acute viral hepatitises A, B, C (according to the form and severity in the Volgograd region) was carried out (Tab. 1). Methods of comparison and grouping were used. From the data of Tab.1 it follows that acute hepatitis A was the most common – 82 (46.9%) cases; acute hepatitis B – 48 (27.4%) cases, it occupies the second place; and acute hepatitis C – 45 (25.7%) cases it occupies the third place.

In 2016–2018, the dynamics of the acute hepatitis A prevalence was characterized by a significant decrease in the morbidity rate from 59.8 to 12.2%, i.e. by 5 times; the morbidity of icteric moderate forms was decreased from 58.8 to 12.3%, i.e. by 4.5 times, although it should be noted that a single case of an icteric form of heavy severity was detected in 2016.

The dynamics of the acute hepatitis B prevalence in 2016–2018 was characterized by a tendency of a decrease in the morbidity rate from 39.5 to 29.2% (by 1.5 times); a decrease in the icteric form of moderate severity from 31.3 to 25% and in the anicteric form of moderate severity from 2.1 to 4.2% was also found out. A single case of acute hepatitis Cencephalopathy has been detected for the whole period.

The dynamics of the acute hepatitis C prevalence in 2016–2018 was characterized by a tendency of an increase from 20 to 42.2% (by 2 times); there was a growth of the icteric form of moderate severity from 11.1 to 20%, of the anicteric form of mild severity – from 2.2 to 11.1%; and of an anicteric form of moderate severity from 4.4 to 11.1%. Two cases of icteric severity were also detected in 2016 and 2017 per annum.

A decrease in the acute hepatitises A and B morbidity is associated with an active use of the hepatitis vaccines [17]. Vaccination of newborns is carried out from the first days of their lives in accordance with the national calendar of vaccinations. Vaccination has also been prescribed for the adult population.

At the 2nd stage of the study, the data of the duration of treatment in hospital environment were reviewed and summarized. The therapy of acute viral hepatitis takes a different time depending on the type of hepatitis, the form and severity of the disease, and goes with clinical guidelines, standards of specialized medical care for patients with acute viral hepatitises [18]. The icteric form of hepatitis is severer than the anicteric form and, therefore, requires a longer treatment. Using the structural-logical method, we can conclude that among icteric forms of hepatitises, it is more difficult to treat acute severe hepatitis B (the treatment duration is 25±5 days).

The icteric form of acute severe hepatitis, occupies the 2nd position as its treatment duration is 19±6 days. Acute hepatitises A and B of the icteric form of moderate severity are in the third position; their treatment duration is 17±7 days. A period from 8 to 16 days is required for the treatment of the anicteric form of mild severity of acute hepatitis C; of moderate severity of acute hepatitises C and B; for the icteric form of acute hepatitis C of moderate severity; and for the icteric form of acute severe hepatitis A (Tab. 2). The cases of the anicteric form of moderate severity of acute hepatitises A and a mild degree of acute hepatitises A and B in hospital environment were not registered.

At the next stage of the study, the range groups of medicinal preparations and the frequency of their prescriptions were cleared up. In the treatment of acute viral hepatitises, pathogenetic therapy (hepatoprotectors, enzymes, vitamins, hormonal medicines, medicines for rehydration and detoxification for parenteral use) was used; besides, etiotropic (interferons and their inducers) and symptomatic kinds of therapy were used. These kinds of therapy also go with the clinical recommendations and standards of specialized medical care [19–23]. The use of groups of medicinal preparations in the corresponding types, forms and degrees of severity of acute hepatitises are presented in Tab. 3–5.

As it follows from Tab. 3, etiotropic therapy was not used for the icteric form of moderate severity of acute hepatitis A, and only interferons in the function of etiotropic therapy, are added to the main treatment of the icteric form of heavy severity of acute hepatitis A. It should be also noted that vitamins were not used at all in this hospital for the treatment of acute hepatitis A.

As Tab. 4 shows, vitamins were not used in the treatment of acute viral hepatitis B either. In its turn, interferon therapy was not used for the icteric form of heavy severity and the anicteric form of moderate severity of acute hepatitis B. Enzymatic and hormonal medicines were not prescribed for the treatment of acute hepatitis B anicteric forms of moderate severity either.

As it follows from Tab. 5, etiotropic therapy was not used in the icteric form of heavy severity and in the anicteric form of mild severity of acute hepatitis C. In the treatment of the anicteric form of moderate severity, only interferons were used in etiotropic therapy. In the treatment of the anicteric form of mild severity, enzyme medicines, hormonal, rehydration and detoxification medicines were not used. Hormonal medicines were not prescribed for the treatment of the acute hepatitis C anicteric forms of moderate severity either.

Thus, the data presented in Tab. 3–5, illustrate the specific treatment of acute viral hepatitises depending on their type, form and severity [24–27].

Tab.6 contains a range of medicinal preparations used in the treatment of acute viral hepatitis in Volgograd Regional Clinical Infectious Diseases Hospital N 1.

The medicinal preparations referring to pathogenetic and etiotropic therapy, have been examined in detail because they directly affect the outcome of the disease. In Tab.6, the groups of medicinal preparations are indicated in accordance with the anatomical-therapeutic-chemical classification [28]. All the presented medicinal preparations belong to the Vital and Essential Drugs List (dated 2016–2018).
### Table 1 – Dynamics of the morbidity of acute viral hepatitises A, B, C during 2016-2018

| Year | Type of hepatitis | Total | Icteric form | Anicteric form |
|------|-------------------|-------|--------------|----------------|
|      |                   |       | Moderate severity | Heavy severity | Moderate severity | Mild severity |
| 2016 | Acute hepatitis A | 49 (59.8%) | 48 (27.4%) | 1 (0.7%) | – | – |
| 2017 | Acute hepatitis A | 23 (28%) | 23 (13.1%) | – | – | – |
| 2018 | Acute hepatitis A | 10 (12.2%) | 10 (5.7%) | – | – | – |
|      |                    | 82 (46.9%) | – | – | – | – |
| 2016 | Acute hepatitis B | 19 (39.5%) | 15 (8.6%) | 3 (1.7%) | 1 (0.5%) | – |
| 2017 | Acute hepatitis B | 15 (31.3%) | 14 (8%) | – | 1 (0.5%) | – |
| 2018 | Acute hepatitis B | 14 (29.2%) | 12 (6.9%) | – | 2 (1.2%) | – |
|      |                    | 48 (27.4%) | – | – | – | – |
| 2016 | Acute hepatitis C | 9 (20%) | 5 (2.8%) | 1 (0.6%) | 2 (1.1%) | 1 (0.6%) |
| 2017 | Acute hepatitis C | 17 (37.8%) | 12 (6.8%) | 1 (0.6%) | 3 (1.7%) | 1 (0.6%) |
| 2018 | Acute hepatitis C | 19 (42.2%) | 9 (5.1%) | 5 (2.8%) | 5 (2.8%) | – |
|      |                    | 5 (25.7%) | – | – | – | – |

### Table 2 – Treatment duration of acute viral hepatitises in hospital environment of Clinical Infectious Diseases Hospital N1 (average statistics)

| Type of hepatitis / form and severity | Icteric form | Anicteric form |
|--------------------------------------|--------------|----------------|
|                                      | Moderate severity | Heavy severity | Moderate severity | Mild severity |
| Acute hepatitis A                    | 17±7 days     | 14±0 days      | – | – |
| Acute hepatitis B                    | 17±7 days     | 25±5 days      | 16±6 days | – |
| Acute hepatitis C                    | 15±5 days     | 19±0 days      | 9±4 days | 8±4 days |

### Table 3 – The use of medicinal preparations groups in the treatment of acute viral hepatitis A

| Group of medicines / form and severity | Icteric form | Moderate severity | Heavy severity |
|---------------------------------------|--------------|------------------|----------------|
| Symptomatic medicines                 | +            | +                |
| Vitamin medicines                     | –            | –                |
| Hepatoprotective medicines            | +            | +                |
| Enzyme medicines                      | +            | +                |
| Hormonal medicines                    | +            | +                |
| Rehydration and detoxification preparations for parenteral use | + | + |
| Interferons                           | –            | –                |
| Interferon inductors                  | –            | +                |

### Table 4 – The use of medicinal preparations groups in the treatment of acute viral hepatitis B

| Group of medicinal preparations / form and severity | Icteric form | Moderate severity | Heavy severity | Anicteric form | Moderate severity |
|-----------------------------------------------------|--------------|------------------|----------------|----------------|------------------|
| Symptomatic medicines                               | +            | +                | +              |
| Vitamin medicines                                   | –            | –                | –              |
| Hepatoprotective medicines                          | +            | +                | +              |
| Enzyme medicines                                    | +            | +                | –              |
| Hormonal medicines                                  | +            | +                | –              |
| Rehydration and detoxification preparations for parenteral use | + | + |
| Interferons                                         | +            | –                | –              |
| Interferon inductors                                | +            | +                | –              |

### Table 5 – The use of medicinal preparations groups in the treatment of acute viral hepatitis C

| Group of medicines/form and severity | Icteric form | Moderate severity | Heavy severity | Anicteric form | Moderate severity | Mild severity |
|-------------------------------------|--------------|------------------|----------------|----------------|------------------|---------------|
| Symptomatic medicines               | +            | +                | +              | +              |
| Vitamin medicines                   | –            | –                | –              | –              |
| Hepatoprotective medicines          | +            | +                | +              | +              |
| Enzyme medicines                    | +            | –                | +              | –              |
| Hormonal medicines                  | +            | +                | –              | –              |
| Rehydration and detoxification preparations for parenteral use | + | + |
| Interferons                         | +            | –                | +              | –              |
| Interferon inductors                | +            | –                | –              | –              |
### Table 6 – The range of medicinal preparations and the frequency of their prescriptions during the study period of 2016–2018

| Medicinal preparations group | Trade name, prescribed dosage, dosage form, route of administration | Number of prescriptions * |
|-----------------------------|---------------------------------------------------------------------|--------------------------|
|                             |                                                                     | 2016 | 2017 | 2018 |
| **Hepatoprotective medicines** |                                                                     |      |      |      |
| Heptor® 400 mg (pills, p.o.) | 1 (1.2%)                                                             | –    | –    | –    |
| Heptoral® 400 mg (lyophilisate, i.v) | 2 (3.1%)                                                         | 7 (8.5%) | 4 (3.9%) |
| Phosphogliv® 65 + 35 mg (capsules, p.o.) | 42 (60%)                                                        | 55 (66.3%) | 75 (70%) |
| Phosphogliv® 2.5 g (lyophilisate, i.v) | 15 (21.4%)                                                        | 3 (3.6%) | 7 (6.7%) |
| Ursode® 250 mg (capsules, p.o.) | 3 (4.3%)                                                             | 15 (18%) | 20 (19.4%) |
| Ursode® 500 mg (capsule, p.o.) | 7 (110%)                                                            | 3 (3.6%) | –    |
| **Total** |                                                                     | 70 (100%) | 83 (100%) | 106 (100%) |
| **Enzyme medicines** |                                                                     |      |      |      |
| Pancreatin 25 units (pills, p.o.) | –                                                                  | –    | 9 (16%) | –    |
| Pancreatin 0.5 (pills, p.o.) | –                                                                  | –    | 1 (2%) | –    |
| Pancreatin 30 units (pills, p.o.) | 1 (100%)                                                          | 1 (100%) | 46 (82%) |
| **Total** |                                                                     | 100 (100%) | 100 (100%) | 56 (100%) |
| **Hormonal medicines** |                                                                     |      |      |      |
| Dexamethasone 8 mg (injection solution, i.v) | 1(14.3%)                                                           | 1 (4.4%) | 1 (4.5%) |
| Prednisolone 5 mg (pills, p.o.) | –                                                                  | 1 (4.1%) | 1 (4.6%) |
| Prednisolone 10 mg (pills, oral) | –                                                                  | 1 (4.1%) | –    |
| Prednisolone 15 mg (pills, p.o.) | –                                                                  | 1 (4.1%) | –    |
| Prednisolone 30 mg (injection solution, i.v) | –                                                                  | 2 (8.3%) | 1 (4.6%) |
| Prednisolone 60 mg (injection solution, i.v) | 6 (25%)                                                           | –    | 13 (6.5%) |
| Prednisolone 90 mg (injection solution, i.v) | 4(57.4%)                                                          | 9 (37.5%) | 11 (50%) |
| Prednisolone 120 mg (injection solution, i.v) | –                                                                  | 1 (12.5%) | 5 (22.7%) |
| **Total** |                                                                     | 7 (100%) | 24 (100%) | 22 (100%) |
| **Rehydration and detoxification preparations for parenteral use** |                                                                     |      |      |      |
| Acesol 400 ml (infusion solution, i.v) | 6 (7.7%)                                                           | 23 (16.5%) | 46 (27.5%) |
| Acesol 450 ml (infusion solution, i.v) | –                                                                  | 2 (1.4%) | –    |
| Acesol 800 ml (infusion solution, i.v) | 1 (1.3%)                                                           | 1 (0.7%) | 2 (1.2%) |
| Glucose 5% – 400 ml (infusion solution, i.v) | 32 (41%)                                                          | 44 (31.7%) | 60 (36%) |
| Glucose 10% – 400 ml (infusion solution, i.v) | 6 (7.7%)                                                          | 19 (13.7%) | 8 (4.8%) |
| Ringer’s solution 400 ml (infusion solution, i.v) | 9 (1.15%)                                                         | 11 (8%) | 4 (2.4%) |
| Ringer’s solution 500 ml (infusion solution, i.v) | 5 (6.4%)                                                          | 7 (5%) | 3 (1.8%) |
| Reamberin® 200 ml (infusion solution, i.v) | –                                                                  | 11 (8%) | –    |
| Reamberin® 250 ml (infusion solution, i.v) | 1 (1.3%)                                                           | –    | –    |
| Remaxol® 200 ml (infusion solution, i.v) | 2 (2.6%)                                                           | –    | 1 (0.6%) |
| Remaxol® 400 ml (infusion solution, i.v) | –                                                                  | –    | 4 (2.4%) |
| Remaxol® 500 ml (infusion solution, i.v) | –                                                                  | –    | 3 (1.8%) |
| Potassium chloride 4% – 10 ml (injection solution, i.v) | 7 (9.0%)                                                          | 7 (5%) | 3 (1.8%) |
| Sodium chloride 0.9% – 400 ml (infusion solution, i.v) | 9 (11.5%)                                                         | 14 (10%) | 33 (19.7%) |
| **Total** |                                                                     | 78 (100%) | 139 (100%) | 167 (100%) |
| **Interferons** |                                                                     |      |      |      |
| Altevir® 3 mln UNITS (injection solution, IM) | 1 (12.3%)                                                          | 1 (16.0%) | 16 (100%) |
| Alpharona® 1.5 million units (lyophilisate, IM) | –                                                                  | 1 (16.7%) | –    |
| Alfarona® 3 million units (lyophilisate, IM) | 6 (75%)                                                            | 4 (66.7%) | –    |
| Layferon® 3 mln UNITS (injection solution, lyophilisate, IM) | 1 (12.5%)                                                          | –    | –    |
| **Total** |                                                                     | 8 (100%) | 6 (100%) | 16 (100%) |
| **Interferon Inducers** |                                                                     |      |      |      |
| Cycoferon® 12.5% -2ml (injection solution, IM) | 8 (100%)                                                          | 2 (100%) | 22 (100%) |
| **Total** |                                                                     | 8 (100%) | 2 (100%) | 22 (100%) |

*Note: 1 prescription = 1 person*

### Table 7 – Dynamics of prices for rehydration and detoxification medicinal preparations used in the treatment of acute viral hepatitises during the period of 2016–2018 (according to the data of the state register of medicinal preparations)

| Group of medicinal preparations | Trade name, prescribed dosage, medicine form, route of administration, package | Limit price, rubles without VAT (per 1 unit) | Price change, % |
|---------------------------------|----------------------------------------------------------------------------------|---------------------------------------------|-----------------|
|                                |                                                                                  | 2016 | 2017 | 2018 | 2018 to 2016 |
| **Rehydration and detoxification preparations for parenteral use** |                                                                                  |      |      |      |              |
| Acesol 400 ml (infusion solution, i.v), medicine bottle | 27.95 | 27.95 | 27.95 | 0.0% |
| Glucose 5% – 400 ml (infusion solution, i.v), medicine bottle | 44.06 | 28.72 | 29.88 | 32.2% |
| Glucose 10% – 400 ml (infusion solution, i.v), medicine bottle | 39.27 | 28.08 | 30.96 | 22.0% |
| Ringer’s solution 400 ml (infusion solution, i.v), medicine bottle | 45.93 | 35.78 | 24.89 | 46.0% |
| Ringer’s solution 500 ml (infusion solution, i.v), medicine bottle | 35.93 | 28.74 | 26.62 | 26.0% |
| Reamberin® 200 ml (infusion solution, i.v) | 128.31 | 132.99 | 138.00 | +7.5% |
| Reamberin® 250 ml (infusion solution, i.v) | 113.83 | 113.83 | 113.83 | 0.0% |
| Reamberin® 400 ml (infusion solution, i.v) | 157.05 | 162.65 | 168.85 | +7.5% |
| Remaxol® 400 ml (infusion solution, i.v) | – | – | 315.00 | – |
| Potassium chloride 4% – 10 ml (injection solution, i.v) ampula | 2.53 | 4.43 | 4.60 | +81.8% |
| Potassium chloride 0.9% – 400 ml (injection solution, i.v) | 33.64 | 23.94 | 33.26 | –1.2% |
The range of medicinal preparations expanded in 2017–2018 in comparison with 2016. Among hepatoprotectors, the most widely used was Phosphogliv® 35+65 mg, among enzyme preparations it was pancreatin 30 UAs, among hormonal preparations prednisolone 90 mg, among rehydration and detoxification preparations – acoso 400 ml, among interferons – 3 mln UAs of Altevir® and among interferon inducers – Cycloferon® 12.5% – 2 ml.

It should be noted that the prescription of the same medicine in different dosages is associated with the type, form and severity of acute hepatitis. The following names and dosages are registered in both – the list of medicinal preparations presented in Tab. 6 and in the state register of medicinal preparations: Phosphogliv® 65+35 mg, Phosphogliv® 2.5 mg, Hepter® 400 mg, Heptral® 400 mg, Ursodez® 250 mg and 500 mg; pancreatin 30 UAs and 25 UAs; dexamethasone 4 mg, prednisone 30 mg and 5 mg; glucose 5%, 10% – 400 ml, potassium chloride 4% – 10 ml, sodium chloride 0.9% – 400 ml, Remaxol® 400 ml, Ringer’s solution 400 ml and 500 ml, Reamberin® 20, 250, 400 ml, acoso 400 ml; Alpharon® 3 mln UAs, Lifferon® 3 mln UAs, Altevir® 3 million UAs; Cycloferon® 12.5% – 2 ml.

According to Tab. 6, during the period of 2016–2018, rehydration and detoxification medicinal preparations were prescribed most often (47% of the entire range), as well as the group of hepatoprotectors (31.7%). In 2018, unlike the previous years, a group of enzyme medicinal preparations began to be prescribed quite widely.

The final stage of the investigation was devoted to the study of price dynamics for the most commonly prescribed medicines of two pharmacotherapeutic groups: medicines for rehydration and detoxification and hepatoprotectors. Since the presented medicines are included in the list of Vital and Essential Medicines, their prices and wholesale surcharges are fixed and controlled by the state. Tables 7, 8 show the dynamics of prices for rehydration and detoxification medicinal preparations, as well as the group of hepatoprotectors.

Since the presented medicines are included in the list of Vital and Essential Medicines, their prices and wholesale surcharges are fixed and controlled by the state. From the data of Tab. 7 it follows, that in the study period in the rehydration and detoxification group (11 items taken as 100%) the prices increased for 3 medicines (27%), Reamberin® 200 ml and 400 ml, potassium chloride 4% – 10 ml; 2 medicines remained in the same price category: aceso 400 ml and Reamberin® 250 ml (18%); the prices decreased for 5 medicines: glucose 5% – 400 ml, glucose 10% – 400 ml, Ringer’s solution 400 ml, Ringer’s solution 500 ml, sodium chloride 0.9% – 400 ml (45%). Remaxol® 400 ml (1%) belongs to new medicines of 2018, therefore its price dynamics is not possible to trace. A significant decrease in the price of 4 medicines (–22–46%), a significant increase in the price of 1 medicine (+81.8%) and a slight increase (+7.5%) for 2 medicines were revealed in comparison with 2016.

Consequently, a larger percentage consists of the medicinal preparations the costs of which have decreased (by 45%). This fact may be associated with an increase in the affordability of medical care, and, accordingly, an increase in medical prescriptions for 2016–2018.

The data of Tab. 8 shows that in the group of 6 hepatoprotectors, the price of 2 medicines did not change (Hepter® 400 mg and Ursodez® 500 mg), the price of other medicines went up from 2.1 to 329.8%. However, this fact did not affect the frequency of prescriptions of this group of medicines, which may be due to an increase in the allocation for the purchase of these items for use in hospital environment. Attention should be also paid to the fact that according to Tab. 6 and 8, the prices for Hepter® 400 mg and Ursodez® 500 mg remained the same in 2016–2018, but their prescription was not registered in 2017 and 2018, which may be due to the lack of their procurement.

**CONCLUSION**

The studies have shown the following. In the period of 2016–2018, there has been a steady tendency of decreasing in the morbidity of acute hepatitis A and B, but in its turn, there has been an increase in the incidence of acute hepatitis C (it was nicknamed “a gentle killer” because of the hidden course of the disease). The main groups of medicines used in hospital environment for the treatment of acute hepatitis A, B and C depending on the form and severity of the disease, have been identified. 3. A study of the range of medicines, the frequency of medical prescriptions and dosages showed that rehydration and detoxification medicines for parental use, and hepatoprotectors are the most commonly prescribed. 4. The dynamics of the prices for the groups of medicines has been studied. It has demonstrated a decrease in prices for rehydration and detoxification medicines (45% of all the numbers of the items) and an increase in prices for medicines of the hepatoprotectors group (66.7% of all the numbers of the items).

The results gained indicate a tendency towards the improvement of medicine provision of patients with acute viral hepatitises, and give an opportunity to consider the ways of their further optimization.

---

**Table 8** – Dynamics of prices for medicines of the group of hepatoprotectors used in the treatment of acute viral hepatitises in the period of 2016–2018 (according to the data of the state register of medicinal preparations)

| Group of medicinal preparations | Trade name, dosage, medicine form, route of administration | Limit price, rubles without VAT (per 1 unit) | Price change,% |
|---------------------------------|----------------------------------------------------------|-----------------------------------------|--------------|
| Hepatoprotective medicines      |                                                          | 2016 2017 2018 2018–2016                |              |
| Hepter® 400 mg (pills, p.o.)    | 44.80 44.80 44.80 0                                  | 0                                         |              |
| Heptral® 400 mg (lyophilisate, i.v.) | 65.31 65.31 280.71 + 329.8 | + 14.4                                    |              |
| Phosphogliv® 0.65 + 0.35 mg (capsules, p.o.) | 8.00 8.81 9.15 | + 12.5%                                   |              |
| Phosphogliv® 2.5 g (lyophilisate, i.v) | 264.45 264.45 270.12 + 2 | + 7.5%                                   |              |
| Ursodez® 250 mg (capsules, p.o.) | 9.03 9.03 12.05 + 33.4 | + 33.4                                   |              |
| Ursodez® 500 mg (capsule, p.o.) | 24.11 24.11 24.11 0                                   | 0                                         |              |
ACKNOWLEDGMENT

The authors are grateful to the head physician of Volgograd Regional Clinical Infectious Diseases Hospital No. 1 Elena V. Dyomina for her assistance in conducting the study.

FINANCIAL SUPPORT

This study did not have any financial support from outside organizations.

AUTHORS’ CONTRIBUTION

All authors equally contributed to the research work.

CONFLICT OF INTERESTS

The authors declare no conflict of interest.

REFERENCES

1. Fedorov AI, Osakovskiy VL, Maksimova SS, Platonov FA. chastota vstrechаемosti polimorfnyh' variantov' gena IL28B i genotipov' virusa gepatita S u naseleniyaYaaku: klinicheskoe soosi [Frequency of occurrence of polymorphic variants of IL28B gene and genotypes of hepatitis C virus in the population of Yakuta: clinical outcomes]. Journal of microbiology epidemiology immunobiology 2017; (2): 96–92. DOI: https://doi.org/10.36233/0372-9311-2017-2-96-92. Russian.

2. Zhebrun AB, Kalinina OV. Virusny'j gepatit S: e'volyuciya'pidemicheskiego processa, e'volyuciya' virusa [Viral hepatitis C: evolution of the epidemiologic process, evolution of the virus]. Journal of microbiology epidemiology immunobiology 2016; (1): 102–112. Russian. DOI: https://doi.org/10.36233/0372-9311-2016-1-102-112. Russian.

3. Alikyeva GM, Maximov CL, Safullin KN, et al. Virusny'j gepatit E. Attending physician. 2012; 48–52. Russian.

4. Deryabin PG. gepatit S: sovremennoe sostoyanie I perspektivy' [Viral hepatitis C: current status and prospects]. Vopr. virologii. 2012; (1): 1–3. Russian.

5. Yushchuk ND, Vengerova YuYa. Infekciyon'noe boleznii: nacional'noe rukovodstvo [Infectious Diseases: National Guide]. M.: GEO-TAR-Media. 2009: 1056 p. Russian.

6. Chulanov VF, Neverov AD, Karandasheva IV. Molokul'yarno-genitcheski eskol'obrazovaniya v e'pidemii' virusnyx' gepatitov' dostizhenniya i perspektivy' [Molecular genetic studies in the epidemiology of viral hepatitis: achievements and prospects]. Epidemiology and Infectious Diseases. Actual issues. 2011; 2: 28–34. Russian.

7. Harwala H, Wong V, Simmonds P. Strury'j gepatitov' razno obshchestvennoye priznaki' [Acute viral hepatitis: to exist existing social strategies need to be changed]? Infect. diseases: news, opinions, training. 2014; 8(3): 23–29. Russian.

8. Uchaykin VF, Cherdenichenko TV, Smirnov AV. Infekciyonnaya ge'patologiya: rukovodstvo dlya vrache'[Infectious hepatitis: a guide for doctors]. M.: GEOTAR-Media. 2012: 627. (In Russ).

9. Shakhgiydan IV, Mikhailov MI, Onischenko GG, Parenter'ny'ye' e'viro'ny'e'egaptov' 'e'pidemii'gy' 'e'pidemii'gy' 'e'pidemii'gy' 'e'pidemii'gy' 'e'pidemii'gy' 'e'pidemii'gy' 'e'pidemii'gy' 'e'pidemii'gy' 'e' (parenteral viral hepatitis, epidemiology, diagnosis, prophylaxis, [Parenteral viral hepatitis (epidemiology, diagnosis, prevention)]. M.: GOU VUNMTS Ministry of Health of the Russian Federation. 2010. Available at: http://www.rmj.ru/articles_6601.htm Russian.

10. Kuzrunova A. gepatoprotektory' [Hepatoprotectors]. Moscow, GEOTAR-Media. 2010; 112 p. Russian.

11. Chained SV, Uleichik SG, Shulenin SN. Gepatoprotektory' [Hepatoprotectors]. Moscow, GEOTAR-Media. 2010; 112 p. Russian.

12. Morozov SV. Gepatoprotektor' v praktike vracha–klinicista [Hepatoprotectors in the practice of a clinician: breast cancer.2010. Available at: http://www.rmj.ru/articles_6601.htm Russian.

13. Pahkomova IG, Upensky YuP. E'scennial'ny'e fosfolipidy': svo'jstva i osobennosti [Essential phospholipids: properties and features]. ConsiliumMedical. Gastroenterology. 2010; 17: 5-9. Russian.

14. Rogov VA, Ganicheva LM. Lekarstvennoe obespechenie hepatoprotektorny' [sic] meditsinskogo processa, e'volyuciya virusa' [Gastroenterology.2011: 630 p. Russian.

15. Rogov VA, Ganicheva LM. Lekarstvennoe obespechenie hepatoprotektorny' [sic] meditsinskogo processa, e'volyuciya virusa' [Gastroenterology.2011: 630 p. Russian.

AUTHORS

Lyudmila M. Ganicheva – Doctor of Sciences (Pharmacy), Associate Professor of the Department of Management and Economics of Pharmacoeconomy, Medical and Pharmaceutical Commodity Science, Volgograd State Medical University. ORCID ID: 0000-0002-5647-0568. E-mail: Ganieva.lm@volgmed.ru

Elena A. Panfilova – Postgraduate Student, Department of Management and Economics of Pharmacy, Medical and Pharmaceutical Commodity Science, Volgograd State Medical University. ORCID ID: 0000-0003-3148-8371. E-mail: Olesya.Panfilova.95@mail.ru

Ivan N. Tyurenkov – Doctor of Science (Medicine), professor, Correspondent Member of the Russian Academy of Sciences, Head of the Department of Pharmacology and Bioinformatics, Faculty of Advanced Medical Studies, Volgograd State Medical University; Head of laboratory of cardiovascular medications, Scientific Center of Drug Research, Volgograd State Medical University. ORCID ID: http://orcid.org/0000-0001-7574-3923. E-mail: fbluv@mail.ru

Julia S. Knyazeva – Assistant, Department of Pharmacology and Biopharmacy, Volgograd State Medical University.

Nelly Sh. Kaisheva – Doctor of Sciences (Pharmacy), Professor of the Department of Pharmaceutical and Toxicological Chemistry, Pyatigorsk Medical Institute – a branch of Volgograd State Medical University. E-mail: Caisheva2010@yandex.ru

Volume VII, Issue 6, 2019

PHARMACY & PHARMACOLOGY

ISSN 2307-9266 e-ISSN 2413-2241

Scientific and Practical Journal

362
Обзоры, лекции
Reviews, Lectures

Фармакогнозия, ботаника
Pharmacognosy, Botany

Фармацевтическая технология и биотехнология
Pharmaceutical Technology and Biotechnology

Фармацевтическая и токсикологическая химия
Pharmaceutical and Toxicological Chemistry

Фармакология и клиническая фармакология
Pharmacology and Clinical Pharmacology

Информационные технологии в фармации
Information Technologies in Pharmacy

Организация и экономика фармацевтического дела
Organization and Economy of Pharmacy

Экономика и менеджмент медицины
Economy and Management of Medicine

Фармацевтическое образование
Pharmaceutical Education

Краткие сообщения
Brief Reports

Дискуссии, рецензии, юбилеи, научные школы, история фармации и фармакологии
Discussions, Referee Reports, Anniversaries, Schools of Thought, History of Pharmacy and Pharmacology